ImmunityBio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ImmunityBio wird ein Gewinn- und Umsatzwachstum von 45.4% bzw. 60.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 44.6% pro Jahr wachsen soll.

Wichtige Informationen

45.4%

Wachstumsrate der Gewinne

44.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	60.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 21

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:IBRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	290	-269	-135	N/A	2
12/31/2025	122	-442	-284	N/A	2
12/31/2024	15	-507	-347	N/A	2
6/30/2024	1	-598	-426	-410	N/A
3/31/2024	0	-601	-413	-389	N/A
12/31/2023	1	-583	-397	-367	N/A
9/30/2023	1	-458	-384	-342	N/A
6/30/2023	1	-473	-387	-335	N/A
3/31/2023	1	-430	-406	-347	N/A
12/31/2022	0	-417	-437	-338	N/A
9/30/2022	1	-400	-409	-318	N/A
6/30/2022	1	-376	-393	-311	N/A
3/31/2022	1	-370	-364	-289	N/A
12/31/2021	1	-347	-308	-274	N/A
9/30/2021	0	-323	-283	-260	N/A
6/30/2021	0	-301	-241	-225	N/A
3/31/2021	1	-264	-210	-201	N/A
12/31/2020	1	-222	-173	-172	N/A
9/30/2020	2	-176	-136	-132	N/A
12/31/2019	2	-158	-156	-152	N/A
12/31/2018	3	-84	-76	-67	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IBRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IBRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IBRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IBRXDie Einnahmen des Unternehmens (60.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: IBRXDie Einnahmen des Unternehmens (51.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IBRX in 3 Jahren voraussichtlich hoch sein wird

ImmunityBio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 86%

Consensus EPS estimates fall by 18%

Consensus revenue estimates increase by 639%, EPS downgraded

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Consensus revenue estimates fall by 86%

Consensus EPS estimates fall by 18%

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc.'s ANKTIVA® Now Covered by More Than a Dozen Insurance Plans Representing over 100 Million Lives Within Months of FDA Approval

ImmunityBio, Inc Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio: All Eyes On Execution Now (Rating Upgrade)

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

ImmunityBio: Anktiva's Launch Demands A Reassessment

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Consensus revenue estimates increase by 639%, EPS downgraded

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Insufficient new directors

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

New major risk - Share price stability

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

ImmunityBio: Buy Low Now Vs. Buy High Later

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

Consensus revenue estimates decrease by 54%, EPS upgraded

New major risk - Financial position

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

New major risk - Share price stability

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Consensus revenue estimates increase by 20%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President exercised options and sold US$183k worth of stock

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

Price target decreased to US$9.00

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio: PDUFA Pending

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain

Consensus forecasts updated

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$20.00

High number of new directors

Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer